Granulocyte-macrophage colony stimulating factor: Evaluation of biopharmaceutical formulations by stability-indicating RP-LC method and bioassay

Biologicals

Volumn 39, Issue 4, 2011, Pages 211-216

  Leal, Diogo Paim ^a   Souto, Ricardo Bizogne ^a   Schutkoski, Renato ^a   Bergamo, Ana Cláudia ^a   Dalmora, Sérgio Luiz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Bioassay; Molgramostim; Recombinant granulocyte macrophage colony stimulating factor; Reversed phase liquid chromatography; Validation

Indexed keywords

ACETONITRILE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TRIFLUOROACETIC ACID;

ANIMAL CELL; ARTICLE; BIOASSAY; CHROMATOGRAPHY; CONTROLLED STUDY; DIODE; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG SPECIFICITY; DRUG STABILITY; FLOW RATE; IN VITRO STUDY; NONHUMAN; PHOTODIODE; PRIORITY JOURNAL; QUALITY CONTROL; REVERSED PHASE LIQUID CHROMATOGRAPHY;

CHROMATOGRAPHY, LIQUID; DRUG STABILITY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LIMIT OF DETECTION; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS;

EID: 79961210164     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.05.002     Document Type: Article

References (32)

1. Hussein A.M., Ross M., Vrendenburgh J., Meisenberg B., Hars V., Gilbert C., et al. Effects of granulocyte-macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), E. coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Eur J Haematol 1995, 55(5):348-356.
2. Armitage J.O. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998, 92(12):4491-4508.
3. Barreda D.R., Hanington P.C., Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev Comp Immunol 2004, 28(5):509-554.
4. Wingfield P., Graber P., Moonen P., Craig S., Pain R.H. The conformation and stability of recombinant-derived granulocyte-macrophage colony stimulating factors. Eur J Biochem 1988, 173(1):65-72.
5. Reichert P., Cook W.J., Ealick S.E., Hammond G.S., Le H.V., Nagabhushan T.L., et al. Crystallization and preliminary X-ray investigation of recombinant human granulocyte-macrophage colony-stimulating factor. J Biol Chem 1990, 265(1):452-453.
6. Tsarbopoulos A., Pramanik N.B., Labdon J.E., Reichert P., Gitlin G., Patel S., et al. Isolation and characterization of a resistant core peptide of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF); confirmation of the GM-CSF amino acid sequence by mass spectrometry. Protein Sci 1993, 2(11):1948-1958.
7. Kitamura T.K., Tance T., Terasawa T. Established and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989, 140(2):323-334.
8. Fogolín B.M., Eberhardt M.O., Kratje R., Etcheverrigaray M. Choice of the adequate quantification method for recombinant human GM-CSF produced in different host systems. Electronic J Biotechnol 2002, 5(3). [on Line], Available from, [accessed June 2010]. http://www.ejbiotechnology.info/content/vol5/issue3/full/6/index.html, 0717-3458.
9. Lee D.L., Sharif I., Kodihalli S., Stewart D.I.H., Tsvetnitsky V. Preparation and characterization of monopegylated human granulocyte-macrophage colony-stimulating factor. J Interferon Cytokine Res 2008, 28(2):101-112.
10. Schwanke R.C., Renard G., Chies J.M., Campos M.M., Junior E.L.B., Santos D.S., et al. Molecular cloning, expression in Escherichia coli and production of bioactive homogeneous recombinant human granulocyte and macrophage colony stimulating factor. Int J Biol Macromol 2009, 45(2):97-102.
11. Marini G., Forno G., Kratje R., Etcheverrigaray M. Recombinant human granulocyte-macrophage colony-stimulating factor: effect of glycosilation on pharmacokinetics parameters. Electronic J Biotechnol 2007, 10(2):271-278.
12. Cebon J., Dempsey P., Fox R., Kannourakis G., Bonnem E., Burgess A.W., et al. Pharmacokinetics of human granulocyte-macrophage colony stimulating factor using a sensitive immunoassay. Blood 1988, 72(4):1340-1347.
13. Kumarasamy R., Bausch J., Kopcha D., Patel S., Mcgonigle E. An enzyme-linked immunosorbent assay (ELISA) for quantitation of adducts of granulocyte-macrophage colony stimulating factor (GM-CSF) and human serum albumin (HSA) in stressed solution mixtures. Pharm Res 1994, 11(3):365-371.
14. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 1999, 185(2):129-188.
15. Longstaff C., Whitton C.M., Stebbings R., Gray E. How do we assure the quality of biological medicines?. Drug Discov Today 2009, 14(1-2):50-55.
16. Almeida B.E., Oliveira J.E., Carvalho C.M., Dalmora S.L., Bartolini P., Ribela M.T.C.P. Analysis of human luteinizing hormone and human chorionic gonadotropin preparations of different origins by reverse-phase high performance liquid chromatography. J Pharm Biomed Anal 2010, 53(1):90-97.
17. Ferreto R.M., Leal D.P., Silva L.M., Nogueira D.R., Dalmora S.L. Validation of a size-exclusion LC method and assessment of rhEPO in pharmaceutical formulation by liquid chromatography and biological assay. J Liq Chromatogr Rel Technol 2009, 32(10):1392-1406.
18. Dalmora S.L., D'Avila F.B., da Silva L.M., Bergamo A.C., Zimmermann E.S. Development and validation of a capillary zone electrophoresis method for assessment of recombinant human granulocyte colony-stimulating factor in pharmaceutical formulations and its correlation with liquid chromatography methods and bioassay. J Chromatogr B 2009, 877(24):2471-2476.
19. Silva M.M.C.G., Lamarre B., Cesaroli E., Rakowska P., Hills A., Bailey M.J.A., et al. Physicochemical and biological assays for quality control of biopharmaceutical: interferon alfa-2 case study. Biologicals 2008, 36(6):383-392.
20. Bristow A.F., Jeffcoate S.L. Analysis of therapeutic growth hormone preparations: report of an interlaboratory collaborative study on growth hormone assay methodologies. Biologicals 1992, 20(3):221-231.
21. De Groot A.S., Scott D.W. Immunogenicity of protein therapeutics. Trends Immunol 2007, 28(11):482-490.
22. Diress A., Lobertskie B., Larocque L., Li X., Alteen M., Isbrucker R., et al. Study of aggregation, denaturation and reduction of interferon alpha-2 products by size-exclusion high-performance liquid chromatography with fluorescence detection and biological assays. J Chromatogr A 2010, 1217(19):3297-3306.
23. Ohgami Y., Nagase M., Nabeshima S., Fukui M., Nakazawa H. Characterization of recombinant DNA-derived human granulocyte macrophage colony stimulating factor by fast atom bombardment mass spectrometry. J Biotechnol 1989, 12(3-4):219-230.
24. Yowell G.G., Fazio S.D., Vivilecchia R.V. Analysis of a recombinant granulocyte macrophage colony stimulating factor dosage form by capillary electrophoresis, capillary isoelectric focusing and high-performance liquid chromatography. J Chromatogr A 1993, 652(1):215-224.
25. ICH. International Conference on Harmonization of Technical Requirements for Registration of pharmaceuticals for human use. Guideline on validation of analytical procedure: text and Methodology Q2(R1), 2005.
26. British Pharmacopoeia, London: The Stationery Office, 2010.
27. Nogueira D.R., Sangoi M.S., da Silva L.M., Todeschini V., Dalmora S.L. Determination of rupatadine in pharmaceutical formulations by a validated stability-indicating MEKC method. J Sep Sci 2008, 31(16-17):3098-3105.
28. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
29. Shabir G.A., Lough W.L., Arain S.A., Bradshaw T.K. Evaluation and application of best practice in analytical method validation. J Liq Chromatogr Related Technol 2007, 30(3):311-333.
30. Ermer J., Miller J.H.M. Method validation in pharmaceutical analysis: a guide to best practice 2005, Wiley-VCH, Weinheim: Germany.
31. European Pharmacopoeia, 7th ed.; Council of Europe: Strasbourg, France, 2011.
32. Dalmora S.L., Masiero S.M.K., Oliveira P.R., Sangoi M.S., Brum L. Validation of an RP-HPLC method and assessment of rhG-CSF in pharmaceutical formulation by liquid chromatography and biological assay. J Liq Chromatogr Rel Technol 2006, 29(12):1753-1767.